SEC Tracker
Get the app

Inhibikase Therapeutics IKT

Inhibikase Therapeutics reported a $20.47 million net loss

Inhibikase Therapeutics (IKT) filed a 10-Q with the SEC on Nov 10, 2026, 4:39 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $20.47 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$0.10 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $51.7 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Inhibikase Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$22.23M−$21.05M−5.6%
Net income−$20.47M−$19.59M−4.5%
Operating cash flow−$17.35M−$12.44M−39%
Cash$51.7M$31.21M+66%

Data on this page was fetched . The filing on SEC.gov is the record.